Physiologic Performance Response to Salbutamol
NCT04615611 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2020-11-04
Summary
This project aims to investigate the individual physiological response to beta2-adrenergic stimulation with salbutamol on performance-related outcomes
Conditions
- Healthy
Interventions
- DRUG
-
salbutamol
inhalation of salbutamol
- DRUG
-
administration of placebo
Sponsors & Collaborators
-
University of Copenhagen
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-11-07
- Primary Completion
- 2021-11-07
- Completion
- 2021-11-07
More Related Trials
-
Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma
NCT00073814 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics of Procaterol in Elite Athletes
NCT05749536 ·Status: COMPLETED
-
Pharmacogenetic of Salbutamol in Pediatric Asthma Crisis
NCT02195258 ·Status: COMPLETED
-
Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults
NCT02802111 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
NCT01747629 ·Status: COMPLETED ·Phase: PHASE3
-
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
NCT01424813 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
NCT06433921 ·Status: RECRUITING ·Phase: PHASE1
-
Genetic Determinants of the Response to Salbutamol Among Asthma Patients
NCT00162396 ·Status: UNKNOWN ·Phase: NA
-
Beta Blocker Therapy in Mild to Moderate Asthmatics
NCT01544634 ·Status: COMPLETED ·Phase: PHASE2
-
Beta Blockers for the Treatment of Asthma
NCT01074853 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma
NCT02127697 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
NCT01056159 ·Status: COMPLETED ·Phase: PHASE1
-
Change in Airway Responsiveness After Allergen Exposure
NCT01699594 ·Status: COMPLETED ·Phase: NA
-
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
NCT00530062 ·Status: COMPLETED ·Phase: PHASE4
-
Diagnosis et Treatment of Asthma in Athlete : Boundary Between Disease and Doping
NCT02655328 ·Status: COMPLETED ·Phase: PHASE4
-
Reversal of Acute β-Blocker Induced Bronchoconstriction
NCT01070225 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes
NCT00375232 ·Status: WITHDRAWN ·Phase: NA
-
A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control
NCT00385359 ·Status: UNKNOWN ·Phase: PHASE4
-
Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
NCT00440245 ·Status: COMPLETED ·Phase: PHASE4
-
Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use
NCT06027606 ·Status: COMPLETED ·Phase: PHASE1
-
Exercise Induced Bronchospasm in Children
NCT00273689 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma
NCT01656811 ·Status: COMPLETED ·Phase: PHASE2
-
INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions
NCT05653024 ·Status: TERMINATED ·Phase: PHASE3
-
Albuterol HFA MDI in Pediatric Participants With Asthma
NCT00577655 ·Status: COMPLETED ·Phase: PHASE3
-
NHFT Effects on Symptatheic Drive of Asthma Patients
NCT05704101 ·Status: COMPLETED